Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cytek Biosciences (CTKB) Change in Intangibles (2022 - 2025)

Historic Change in Intangibles for Cytek Biosciences (CTKB) over the last 4 years, with Q3 2025 value amounting to -$2000.0.

  • Cytek Biosciences' Change in Intangibles rose 7500.0% to -$2000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $83000.0, marking a year-over-year decrease of 6757.81%. This contributed to the annual value of $204000.0 for FY2024, which is 1396.65% up from last year.
  • Per Cytek Biosciences' latest filing, its Change in Intangibles stood at -$2000.0 for Q3 2025, which was up 7500.0% from $74000.0 recorded in Q2 2025.
  • In the past 5 years, Cytek Biosciences' Change in Intangibles registered a high of $148000.0 during Q2 2024, and its lowest value of -$8000.0 during Q3 2024.
  • In the last 4 years, Cytek Biosciences' Change in Intangibles had a median value of $55000.0 in 2023 and averaged $48083.3.
  • The largest annual percentage gain for Cytek Biosciences' Change in Intangibles in the last 5 years was 16909.09% (2024), contrasted with its biggest fall of 11269.84% (2024).
  • Cytek Biosciences' Change in Intangibles (Quarter) stood at $80000.0 in 2022, then fell by 23.75% to $61000.0 in 2023, then tumbled by 85.25% to $9000.0 in 2024, then crashed by 122.22% to -$2000.0 in 2025.
  • Its Change in Intangibles stands at -$2000.0 for Q3 2025, versus $74000.0 for Q2 2025 and $2000.0 for Q1 2025.